Skip to main navigation
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Contact
  • Programs
    • HBV
    • Pipeline
  • Patients
    • Commitment
    • Clinical Trials
    • Resources
  • Sustainability
    • Overview
    • Business Ethics
    • Access to Health Care
    • Human Capital
    • Environment, Health and Safety
  • Collaborations
  • Investors
    • News & Events
    • Corporate Governance
    • Financials & Filings
    • Stock Information
  • Careers
    • Culture
    • Benefits
    • Opportunities
On the
  • Press Releases
  • Events & Presentations

Press Releases

Feb 26, 2021 Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
View HTML
PDF Version
Feb 25, 2021 Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
View HTML
PDF Version
Feb 25, 2021 Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
View HTML
PDF Version
Feb 19, 2021 Assembly Bio Announces Upcoming Investor Events
View HTML
PDF Version
Feb 05, 2021 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
View HTML
PDF Version
Shareholder Tools Print Email Alerts Printed Materials RSS News Feeds
Search Investors

Contact Us

833.509.4583
info@assemblybio.com
About Programs Patients Collaborations Investors Careers

© 2021 Assembly Biosciences, Inc.